Specialist pharma construction
Skanska's US subsidiary sets up dedicated group aimed at designing
and building FDA-compliant facilities for the pharma/biotech
Novo expands engineering services in Sweden
Novo Nordisk Engineering, a consultancy firm operating as a
subsidiary of Danish pharmaceutical company Novo Nordisk, has
opened an office in Sweden.
GSK sweetens Montrose plant closure
Pharmaceutical major GlaxoSmithKline has set aside £1 million
(€1.4m) to soften the blow of selling its bulk active ingredient
manufacturing facility in Montrose.
Boehringer opens €255m biopharma plant
Boehringer Ingelheim doubles its biopharmaceutical production
capacity at a stroke with the completion of a new plant at its site
in Biberach, Germany; a similar expansion in Austria is also
Thermo to buy Jouan for €110m
Thermo Electron has fulfilled a promise to make acquisitions in the
laboratory and life sciences area by announcing plans to acquire
French lab equipment provider Jouan SA.
Gauging new product need in the drug industry
A new report has suggested that an average-sized, top 20 drug
company only needs to produce two new products every three years to
maintain growth rates.
CRO industry coming under pressure
Contract research organisation (CRO) revenues have been growing
strongly as a result of drug developers' need to reduce R&D
costs while shortening product evaluation times. However, as demand
for more efficient preclinical...
Dolly firm faces the chop
The axe looks set to fall on Scottish biotechnology company PPL
Therapeutics now that the company put itself up for sale, having
failed to convince investors of a rescue plan.
Maiden results and new deals for BioProgress
Capsule technology company BioProgress has reported its first set
of interim results since becoming an AIM-listed company, as well as
a distribution deal with Hoefliger.
Swiss expansion for Ferring
Ferring Pharmaceuticals has unveiled plans to invest €90 million in
a state-of-the-art production site in Saint-Prex in Switzerland.
Profile on the verge of take-off?
Profile Therapeutics has reported strong growth in sales and a
reduced operating loss for the year-ended June 30, and expects this
trend to continue as its R&D efforts in improved nebuliser
technologies come to fruition.
Pharma holds back H&R WASAG
H&R WASAG saw its pre-tax profits halve in the first six months
of this year, hit by high and volatile raw material costs that
impacted its flagship pharmachem division.
CSS opens £25m plant in Northern Ireland
Chemical Synthesis Services has opened a new, £25 million (€36
million) facility in Craigavon, Northern Ireland, improving its
drug development and analysis services.
Whatman sees signs of recovery
UK-based separations specialist Whatman saw its turnover drop in
the first half of 2003, but operating profits leap on back of its
Manufacturing in the ascendancy at Intercare
UK pharmaceutical manufacturing and distribution company Intercare
has posted a record set of results for the first half of 2003.